Tests CD79b-19 CAR T cells in adults with relapsed or refractory lymphoma
Tests CD79b-19 CAR T cells in adults with returned or non-responding non-Hodgkin lymphoma.
Key facts
- Who runs it
- Marcela V. Maus, M.D.,Ph.D.
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 24 people, planned
- Started
- 26 Oct 2023
- Expected to end
- 1 Aug 2028
- Type of study
- Interventional
- Treatments tested
- CD79b-19 CAR T cells
- Cyclophosphamide
- Fludarabine
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose non-Hodgkin lymphoma came back or did not respond to earlier treatment. It tests CD79b-19 CAR T cells.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory non-Hodgkin lymphoma: follicular, marginal zone, diffuse large B-cell (including transformed follicular, primary mediastinal, high-grade B-cell and grade 3b follicular) or mantle cell lymphoma. Disease must be measurable. Follicular and marginal zone lymphoma must have returned or not responded after 2 or more earlier lines of treatment. Large B-cell lymphoma needs 2 or more earlier lines, a relapse after a stem cell transplant using the person's own cells, or being unable to have that transplant.
- Earlier treatment
- Mantle cell lymphoma: earlier treatment may include anthracycline or bendamustine chemotherapy, an anti-CD20 antibody and a BTK inhibitor. For TP53 mutation: earlier BOVen (zanubrutinib, obinutuzumab, venetoclax) may count. No other cancer treatment between cell collection and treatment, except low-dose steroids. For one arm (B.2): no earlier CD19-directed cell therapy.
Main reasons for not taking part
- Active lymphoma in the brain or spinal cord (CNS disease)
- Active uncontrolled infection
- Serious heart problems, such as class III or IV heart failure or a heart attack in the last 3 months
- Another cancer treated in the last 3 years or not in complete remission
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Voluntarily sign informed consent form(s)
- ≥18 years of age at the time of signing informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥60%)
- Diagnosis of histologically or cytologically confirmed relapsed/refractory (R/R) Non Hodgkins lymphoma as defined as one of the following (Note: only patients with indolent lymphomas that warrant treatment should be treated, this will include those with local symptoms due to progressive/bulky disease, compromised organ function, B symptoms, extra-nodal disease, cytopenias from marrow involvement and/or in the opinion of the treating physician believe that any of the above symptoms or potentially life threatening involvement will occur will be treated):; Follicular Lymphoma (FL) grade 1, grade 2, or grade 3a; R/R disease after 2 or more prior lines of systemic therapy; Marginal Zone Lymphoma (MZL) nodal of extranodal:; R/R disease after 2 or more prior lines of systemic therapy; Diffuse large B-cell lymphoma (DLBCL), including transformed follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL) and grade 3b Follicular Lymphoma (FL); R/R disease after 2 or more prior lines of therapy OR; Relapsed following autologous SCT, OR; Ineligible for autologous SCT; Mantle cell lymphoma; R/R disease as defined by disease progression after last regimen (including autologous SCT) OR; Refractory disease as defined as failure to achieve a CR to last regimen; a. For all patients (including those with TP53 mutations) prior therapy may include:; Anthracycline or bendamustine-containing chemotherapy AND; Anti-CD20 monoclonal antibody therapy AND; BTKi therapy (progression does not have to be documented on BTKi). OR; b. For patients with TP53 mutations, prior therapy may include:; Prior therapy with BOVen (zanubrutinib, obinutuzumab, and venetoclax)
- Subjects must have measurable disease according to appropriate disease specific criteria
- Adequate absolute lymphocyte count (ALC > 100 cells/ul) within one week of apheresis
- Adequate bone marrow function defined by absolute neutrophil count (ANC) >1000 cells/mm3 without growth factor support (filgrastim within 7 days or pegfilgrastim within 14 days) and untransfused platelet count >50,000 mm3
- Left ventricular ejection fraction > 40%
- Adequate hepatic function defined by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 × upper limit of normal (ULN) and direct bilirubin < 1.5 × ULN
- Adequate renal function defined by creatinine clearance >60 ml/min using the Cockcroft-Gault formula
- The effects of CD79b-19 CAR T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to leukapheresis. Women of childbearing potential are required to use adequate contraception for up to 1 year post CD79b-19 CAR T cell infusion. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners of childbearing potential treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and until 6 months after last CD79b-19 CAR T cells administration
- Ability and willingness to adhere to the study visit schedule and all protocol requirements
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥60%, see Appendix A)
- No active, uncontrolled, systemic bacterial, viral, or fungal infection. If febrile, the patient must have negative blood cultures x48 hours at time of cell infusion AND on appropriate broad spectrum antibiotic therapy
- Oxygen saturation >92% on room air while awake
- No additional anti-cancer therapy since leukapheresis excluding steroids at or below physiologic dosing; Infusion may be delayed by up to 5 days after completion of LD chemo, without sponsor approval, in the event that these issues resolve in that time frame; The above criteria need to be met to start treatment (for both initiation of lymphodepletion and cell infusion)
Who cannot take part
- Treatment with an any investigational cellular therapy within 8 weeks prior to apheresis
- Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine or systemic steroids above physiologic dosing). Intermittent topical, inhaled, or intranasal corticosteroids are allowed
- Ongoing systemic immunosuppression for acute and/or chronic GVH as a result of previous allogeneic bone marrow transplant and at least 12 weeks out from prior allogeneic SCT
- Subjects with unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the previous 3 months
- Pregnant or lactating women. Pregnant women are excluded from this study because CAR-79b-19 T cell drug product is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-79b-19 T cell drug product, breastfeeding should be discontinued if the mother is treated with CAR-79b-19 T cell drug product; Additional Exclusion Criteria for Leukapheresis for Part B, Arm B.2:
- Prior CD19-directed cellular therapy
- Any systemic anti-cancer therapy within 1 weeks or 5 half-lives of leukapheresis, whichever is shortest, excluding steroids (prednisone) at or below physiologic dosing (5mg)
- Presence of active CNS disease
- Significant co-morbid condition or disease which in the judgment of the Principal Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, and/or recent significant traumatic injury
- Active, uncontrolled, systemic bacterial, viral, or fungal infection
- Subjects with a history of class III or IV congestive heart failure or with a history of non- ischemic cardiomyopathy
- Subjects with arterial vascular disease such as history of cerebrovascular accident or peripheral vascular disease requiring therapeutic anti-coagulation
- Subjects with history of a new pulmonary embolism (PE) /deep vein thrombosis (DVT) within 6 months of beginning lymphodepletion requiring ongoing anticoagulation
- Subjects with second malignancies if the second malignancy has required therapy in the last 3 years or is not in complete remission; exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy other than hormonal therapy
- No bispecific T cell engagers within 6 months of leukapheresis
- No bendamustime within 6 months of leukapheresis
Where in United States
- Massachusetts General HospitalBoston, United StatesContact: Matthew Frigault, MDTaking people
About the trial
What the trial wants to find out
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells.
Read full original descriptionShow less
This research study involves the study drugs:
* CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
The group in the trial
- CD79b-19 CAR T cellsTreatment being tested
Prior to receiving CD79b-19 CAR T cells, participants will undergo two preparatory processes: * Leukapheresis: During Week -3 white blood cells will be collected. * Lymphodepletion: On days, -5 to -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes CD79b-19 CAR T cells will be administered intravenously on day 0 only. The dose you will receive will depend on the number of participants who have been enrolled prior and how well the dose was tolerated. The CD79b-19 CAR T cells will be administered over approximately 1 hour.
Treatment: CD79b-19 CAR T cells, Cyclophosphamide, and Fludarabine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
- Plain-language title
- Tests CD79b-19 CAR T cells in adults with relapsed or refractory lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 October 2026